Drugs / Aramchol
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07251712 | Dec 2025 → Apr 2026 overdue | — | Galmed Pharmaceuticals Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT05874336 | Jun → Aug 2020 | metabolic dysfunction-associated steatohepatitis | Galmed Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04480827 | Feb 2020 → Mar 2022 | — | Galmed Research and Development, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03774173 | Dec 2018 → Feb 2019 | — | Galmed Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03760848 | Nov 2018 → Feb 2019 | — | Galmed Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 1 | NCT00776841 | Sep 2008 → Sep 2009 | — | Galmed Medical Reserch | Completed | No outcome recorded |
| Phase 24 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT02684591 | Jan 2016 → Feb 2018 | HIV infectious disease, NAFLD1 | University of California, San Diego | Completed | Missed primary |
| Phase 2 | NCT02279524 | Apr 2015 → May 2018 | fibrotic liver disease, metabolic dysfunction-associated steatohepatitis | Galmed Research and Development, Ltd. | Completed | Missed primary |
| Phase 2 | NCT02325492 | Oct 2014 → Oct 2015 | gallstones | Galmed Pharmaceuticals Ltd | Terminated | No outcome recorded |
| Phase 2 | NCT01094158 | Nov 2010 → Nov 2011 | NAFLD1, metabolic dysfunction-associated steatohepatitis, metabolic syndrome X | Galmed Medical Reserch | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT04104321 | Sep 2019 → Dec 2022 | metabolic dysfunction-associated steatohepatitis | Galmed Research and Development, Ltd. | Suspended | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT02803996 Comparator | May → Sep 2016 | — | Galmed Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02374437 Comparator | Apr → Dec 2014 | — | Galmed Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 2 | NCT06095986 Comparator | Jun 2025 → Sep 2026 | primary sclerosing cholangitis | Galmed Pharmaceuticals Ltd | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aramchol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01094158 ↗ |
| Action | Inhibit | “Aramchol inhibits the liver enzyme Stearoyl Coenzyme A Desaturase (SCD).” NCT01094158 ↗ |
| Modality | Other / unclassified | “fatty acid-bile acid conjugate” PMID 24815326 ↗ May 2014 |
| Route | Oral | “Oral Aramchol at dose 30 mg to 900 mg” NCT00776841 ↗ |
| Target | SCD | “Aramchol inhibits the liver enzyme Stearoyl Coenzyme A Desaturase (SCD).” NCT01094158 ↗ |